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Viral load (VL) of human immunodefi-
ciency virus (HIV) in the HIV-infected 
partner is the best described correlate of 
heterosexual HIV transmission, with each 
order of magnitude of VL associated with 
a 2- to 3-fold increased risk for the HIV-
uninfected partner (both male-to-female 
and female-to-male) [1]. While antiretro-
viral therapy (ART) can dramatically reduce 
the rate of HIV transmission [2], placing this 
at the forefront of HIV prevention strategies, 
its effectiveness is contingent on consistent 
VL suppression [3]. Because a large propor-
tion of HIV transmission occurs via sexual 
intercourse, the assumption was that by re-
ducing plasma VL (PVL), ART is in parallel 
reducing genital VL (GVL). However, if this 
was not the case, the hypothesis was that 
suppressed PVL might not predict instances 
of onward HIV transmission due to “iso-
lated” mucosal HIV shedding (PVL neg-
ative but GVL positive). Studies in semen 
have demonstrated that local shedding can 
be persistent and at levels corresponding to 
“transmissible” virus [4]. Indeed, although 
PVL has correlated with GVL in studies of 
both male and female genital secretions [5], 
this correlation was typically modest, and 
many found that a proportion of individuals 
are GVL positive even though PVL is unde-
tectable, suggesting that local factors could 
influence the risk of transmission [6]. This 
was further supported by evidence that 
GVL also correlated with HIV transmission 
risk, independent of PVL [7]. Together these 
studies have suggested that a better under-
standing of how often, and in what circum-
stances, mucosal shedding of HIV occurs 
during effective HIV treatment might have 
important HIV-prevention implications.
In this issue of the Journal of Infectious 
Diseases, King et al report a large prospec-
tive study of >1100 African women on ART 
carried out to better understand the extent 
of, and potential contributors to, genital 
HIV shedding. This large study utilized 
specimens from 3 HIV clinical trials span-
ning several central and southern African 
countries. Genital HIV RNA was detected 
in 6% of >1400 visits made by women with 
undetectable PVL and 24% of approxi-
mately 400 visits by women with detectable 
PVL. Both of these estimates are well below 
those observed in untreated HIV infec-
tion, where approximately three-quarters of 
individuals are GVL positive. Importantly, 
<1% of women with suppressed PVL shed 
GVL consistently. Although there was no 
change in the magnitude of viral shedding, 
there was a decrease in the proportion of 
visits with genital shedding with increased 
ART duration in those with undetectable 
PVL. This is consistent with a previous re-
port that showed a decline in shedding up 
to 18  months on ART [8], and suggests 
that the source of HIV mucosal shedding 
may decrease relative to the rate of PVL 
suppression. The observed rate of genital 
shedding of 6% is slightly lower, but gener-
ally consistent with, rates reported in pre-
vious studies (typically 10%–15%) that have 
had more limited power (n  =  100–200) 
[9–11]. It is also consistent with studies that 
have suggested that ART leads to a rapid de-
cline in GVL (more rapidly than PVL) [12], 
suggesting that ART is highly effective in re-
ducing GVL levels.
One important contribution added by 
this study is the large sample size and in-
clusion of multiple study cohorts. While 
this increases the accuracy and general-
izability of reported shedding rates, it also 
allows better characterization of predic-
tors of shedding, which could be key to fu-
ture interventions. The main predictors of 
genital shedding among women with un-
detectable PVL included advanced WHO 
classification of HIV disease stage and 
presence of genital ulcers or cervical ten-
derness, followed by type of ART regimen. 
The extent of HIV disease was found to 
influence HIV shedding in previous work 
[13], and may be indicative of increased 
systemic immune activation and immune 
dysregulation during chronic HIV infec-
tion. One might infer that with earlier ART 
initiation, as per all current guidelines, the 
rate of HIV shedding may decline further.
A long-standing hypothesis has sug-
gested that local events may influence HIV 
shedding, as is supported by the finding 
that HIV shedding was associated with 
surrogates of genital inflammation (which 
are also a risk factor for HIV acquisition 
[14]). Indeed, this finding is supported 
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by several early, smaller studies that have 
suggested associations between cervical 
HIV shedding and increased frequencies 
of immune cells [15–18], higher mucosal 
cytokine levels [19, 20], cervical infections, 
herpes simplex type 2 reactivation, and/or 
vaginal dysbiosis [21–24]. Although the 
authors did not observe any effect of chla-
mydia and gonococcal infections on HIV 
shedding, this is likely due to low preva-
lence of these STIs. One weakness of the 
study is that many potential biological 
correlates of shedding were not measured, 
resulting in inability to determine the im-
pact of these and whether they may have 
confounded the other predictors. One 
potential focus of future studies could be 
cytomegalovirus (CMV), an important 
opportunistic pathogen in HIV-infected 
individuals. In individuals with ART-
suppressed HIV infection, CMV often 
reactivates asymptomatically and contrib-
utes to persistent immune activation and 
ongoing inflammation [25, 26]. However, 
because the HIV shedding observed by 
King et al was relatively uncommon, even 
if the specific factors predicting HIV shed-
ding were to be identified, intervening may 
not carry significant public health impact 
if the predicted event is relatively rare be-
cause of the effectiveness of ART itself.
Another open question, related to local 
drivers of HIV shedding, is the under-
lying source of HIV in the genital mu-
cosa. The extent to which viral shedding 
is due to the blood supply to the mucosa 
and/or due to local viral reservoirs is still 
unclear and likely depends on both the 
extent of viral replication at different an-
atomical sites and on levels of local and 
systemic inflammation. Blood flow could 
deliver cell-free virus to tissues and/or 
enhance the infection of local CD4 T 
cells. A  case can also be made for com-
partmentalization of virus, as has been 
observed in virologic differences between 
the genital and systemic compartments 
[27]. One interpretation of the data, in-
cluding the modest correlation between 
PVL and GVL, coupled with the obser-
vation of local drivers of HIV shedding, 
might suggest that HIV shedding can 
result from both infected tissue and new 
virus that is introduced from systemic 
circulation.
This study also addresses the question 
of the degree to which different ARVs are 
able to access different tissues. One recent 
study in SIV-infected nonhuman primates 
has suggested that extensive SIV RNA can 
be detected in multiple organ systems [28]. 
Suboptimal tissue penetration of the ARVs 
may not fully suppress viral production in 
the tissues, a result that is dependent on 
physiochemical properties of the ARVs as 
well as levels of tissue inflammation [29]. 
There are mixed reports in the literature 
regarding ART regimen and HIV mucosal 
shedding, and this issue is not entirely clari-
fied by the current study. Future studies that 
do not rely on self-reported ART adherence 
data and instead female reproductive tract 
and plasma drug level measurements may 
provide more clarity. The choice of reg-
imen could also be a confounding factor, if 
patients with different outcomes are given 
different regimens in the clinic; this is not 
really addressed by King et al. Finally, this 
issue will need to be re-evaluated as newer 
ART regimens become available, particu-
larly those containing integrase inhibitors.
Finally, although these results support 
the concept that women on ART with sup-
pressed PVL may still be at risk of transmit-
ting HIV, the extent to which HIV shedding 
defined by GVL contributes to actual HIV 
transmission remains unclear. No HIV 
transmissions to HIV uninfected partners 
were observed by King et  al (all partici-
pants were in an HIV-discordant couple). 
This supports a previous report in which 
approximately 14 000 exposures did not 
lead to HIV transmission despite detection 
of shedding [13], evidence from an HIV 
Prevention Trials Network study (HPTN 
502), where the only transmission was in a 
person yet to suppress PVL [2], and the lack 
of HIV transmission from PVL-suppressed 
individuals in the PARTNER study [30]. 
Therefore, the low rates of HIV shedding 
observed by King et al should be reassuring 
to those who are implementing test-and-
treat strategies of HIV prevention. These 
data combined with previously published 
studies suggest that because HIV shedding 
is relatively uncommon and not associated 
with significant rates of HIV transmission, 
efforts to address the major challenges of 
increasing rates of HIV testing and achiev-
ing sustained ART adherence may be most 
critical for success in combination HIV pre-
vention [31]. That being said, the develop-
ment of additional therapeutic modalities 
to reduce mucosal inflammation, microbial 
dysbiosis, and other genital infections—the 
burden of which is higher in HIV-positive 
individuals and which contribute to signifi-
cant morbidity—would be a major benefit to 
women globally, regardless of whether there 
are any implications for HIV transmission.
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